Status:
UNKNOWN
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
Lead Sponsor:
Air Force Military Medical University, China
Conditions:
Disease Free Survival
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concur...
Detailed Description
Cervical cancer is the most common malignant tumor of the female productive system in developing countries and regions. Since five large-sample randomized controlled clinical trials have reported that...
Eligibility Criteria
Inclusion
- Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
- 2018FIGO clinical stage I-IIIC disease
Exclusion
- 1， Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years; 2， Prior systemic chemotherapy within the past three years; 3， Prior radiotherapy to the pelvis or abdomen ; 4， Distant metastasis; 5， Severe, active co-morbidity; 6， patients with FIGO stage IVA 7， Bevacizumab is prohibited to the patients with active bleeding and hypertension
- \-
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04138992
Start Date
August 1 2020
End Date
May 31 2022
Last Update
June 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China, 710032